Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report [Seeking Alpha]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Seeking Alpha
The company's cash position remains healthy, providing support for its corporate, commercial, and pipeline initiatives. Investors should look out for updates on commercial information, efforts to expand olutasidenib, and the development of other products beyond TAVALISSE and REZLIDHIA. Looking for a helping hand in the market? Members of Compounding Healthcare get exclusive ideas and guidance to navigate any climate. Learn More » It has been over years since my last Rigel Pharmaceuticals ( NASDAQ: RIGL article, where I discussed TAVALISSE's prospects as a COVID-19 treatment option. Before that article, I frequently covered the company's long-term potential thanks to TAVALISSE's growth and Rigel's promising pipeline. Unfortunately, the company's COVID-19 endeavors were not fruitful and the RIGL share price has been cut in half. Despite my lack of coverage, my interest in Rigel has not faded, and I have made RIGL a "Top Idea" in the Compounding Healthcare investing group. I made
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Announces Conference Call and Webcast to Report First Quarter 2024 Financial Results and Business UpdatePR Newswire
- Rigel Pharmaceuticals: No Respect With Little Justification, Worth Considering A Buy [Seeking Alpha]Seeking Alpha
- Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)PR Newswire
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma [Yahoo! Finance]Yahoo! Finance
- Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & LymphomaPR Newswire
RIGL
Earnings
- 3/5/24 - Beat
RIGL
Sec Filings
- 4/12/24 - Form 8-K
- 4/10/24 - Form ARS
- 4/10/24 - Form DEFA14A
- RIGL's page on the SEC website